BCC Research, a leading science and technology market research company, projects that sales of chronic pain neurostimulation devices will grow to $2.8 billion in 2018. Chronic pain is the largest segment of the neurostimulation device market; the gastrointestinal category is the second. Forecasts anticipate the growing need for pain management, as well as increased understanding of what these devices offer. They are currently used in clinical trials or being developed for use in Parkinson’s disease, sexual dysfunction, drug addiction, and other disorders.
This report includes trends, estimates, and projections through 2018. Reasons for projected growth include the aging of the population and technological advances of the devices. Clinicians and experts in neuroscience and neurosurgery are expected to gain the most from the data contained in this Neurostimulation: Technologies and Global Markets report.
To read more of the article, click here.
For more information, click here.
Posted on April 21, 2014